Instituto de Cardiologia de Corrientes

Corrientes W3400AMZ

1 studies enrolling now · 7 studies all time

What they study most

Cardiovascular Diseases, Connective Tissue Diseases, Dyslipidemia, Familial Primary Pulmonary Hypertension, Hypertension, Hypertension, Pulmonary, Lung Diseases, Myocardial Infarction, PAH, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Respiratory Tract Disease

Studies at this site

• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension — Enrolling by invitation
• Selexipag (ACT-293987) in Pulmonary Arterial Hypertension — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension — Completed
• DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension — Stopped early